Compare GVH & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | NOTV |
|---|---|---|
| Founded | 2016 | 1974 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 10.8M |
| IPO Year | 2023 | 1997 |
| Metric | GVH | NOTV |
|---|---|---|
| Price | $6.00 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $80.00 | $1.50 |
| AVG Volume (30 Days) | 150.7K | ★ 960.0K |
| Earning Date | 02-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | $102,768.97 | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.03 | $0.22 |
| 52 Week High | $10.74 | $3.31 |
| Indicator | GVH | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 85.92 | 52.74 |
| Support Level | $4.02 | $0.24 |
| Resistance Level | N/A | $0.41 |
| Average True Range (ATR) | 0.65 | 0.03 |
| MACD | 0.23 | 0.00 |
| Stochastic Oscillator | 89.05 | 44.01 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.